ReviewNPJ precision oncology2025
Deciphering the liver's role in pancreatic cancer metastasis: pathways and therapeutic approaches.
Review in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Pretreatment CONUT Score and Overall Survival in Patients with Metastatic Pancreatic Adenocarcinoma Receiving First-Line Chemotherapy: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Safe and Effective Histotripsy Ablation of Human Liver Tumors in a Genetically Modified Porcine Model.Cancers · 2026Article
- Pancreatic Cancer-Derived Small Extracellular Vesicles Remodel Hepatic Pre-Metastatic Niche via Hybrid Epithelial-Mesenchymal States.International journal of molecular sciences · 2026Article
- A MUC1-ALIX complex regulates extracellular vesicle cargo loading with activated SRC to enhance pancreatic cancer progression.Cancer letters · 2026Article
- The abscopal effect of IRE combined with anti-PD-1 achieves local ablation and systemic control of PDAC.bioRxiv : the preprint server for biology · 2026Article
- Peritoneal metastasis in pancreatic cancer: molecular mechanisms, microenvironmental remodeling, and emerging intraperitoneal interventions.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver frequently serves as a site for metastasis in pancreatic ductal adenocarcinoma (PDAC), attributable to its extensive blood supply and supportive microenvironment, which fosters the formation of a pre-metastatic niche that facilitates tumor dissemination. Deciphering the mechanisms underlying niche formation has historically been challenging, requiring detailed investigation into the interactions between primary tumors and metastatic sites. Although these interactions were previously poorly understood, recent advances have elucidated key pathways involved in this process. These insights have been enabled by cutting-edge techniques, including spatial histological mapping, single-cell sequencing, and the identification of novel molecular markers in pancreatic and hepatic metastases. Furthermore, this review revisits and critically evaluates Paget's 'seed and soil' hypothesis in light of current evidence from studies on liver metastatic niches. This review aims to deepen our understanding of liver metastasis in PDAC, with potential implications for the development of targeted therapies and improved clinical outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.